pazopanib has shown a median PFS of 4.6 months in the PALETTE trial24. On the other hand, patients with the poorest prognosis could benefit more from well-planned palliative and supportive care than chemotherapy. In this retrospective analysis of patients with L-sarcoma treated with trabectedin in...
Women who achieve a response to initial adjuvant chemotherapy may be candidates for maintenance therapy, with the goal of inducing a lasting remission or prolonging the disease-free interval before recurrence. The rationale for maintenance therapy is to delay disease progression by eliminating residual,...
50% of patients are initially non-responsive to chemotherapy, according to clinical studies [45]. Drug administration and prolonged exposure to a drug can lead to acquired resistance [46]. 90% of cancer-related deaths are due to resistance mechanisms. Indeed, anticancer agents are used ...
Such a ratio would not reflect absolute circulating endothelial cell numbers in blood samples because of inclusion of leukocytes, which are strongly influenced by infections or cancer therapies, including chemotherapy or radiation. Therefore, accurate assessment of the number of circulating endothelial ...
chemotherapy and radiation, and hence a major goal in sarcoma research has been to develop molecular targetted therapies.30–32 Our observations that TBX3 expression is elevated in sarcoma cell lines and patient-derived tissue sections repre- sentative of both simple (synovial sarcoma) and complex...
Polyethoxylated castor oil is required to make the chemotherapy agent paclitaxel water soluble before administration. Unfortunately, this excipient is also associated with hypersensitivity reactions, frequently necessitating pretreatment with steroids and ultimately compromising drug delivery to the tumour [17]....
Renal cell carcinoma is often treated by surgery and targeted therapy (Chung et al, 2003; Gustafsson et al, 2009a) as it is relatively resistant to standard radiation therapy and cytotoxic chemotherapy (Deschavanne and Fertil, 1996; Ku et al, 2014). Increasing attention has been drawn to ...
27 Here, we describe a patient with a spindle cell sarcoma presenting a p.G12V KRAS mutation. The patient displayed early disease progression following surgical resection, was not a candidate for doxorubicin chemotherapy and did not respond to the multikinase inhibitor pazopanib. Despite being in ...
Immune cells, such as tumor associated macrophages (TAMs), can affect the response of tumor cells to chemotherapy through a process called environment-mediated drug resistance. A study by Amit et al. showed that TAMs can secrete the enzyme cytidine deaminase which metabolizes gemcitabine into its ...
enzalutamide and abiraterone acetate, anti-oestrogens, such as tamoxifen, or aromatase inhibiting or steroid modifying agents, such as anastrozole, letrozole, fulvestrant and exemestane, ix) a PARP inhibitor, particularly olaparib, or x) another chemotherapy drug, particularly L-asparaginase or bortezomib...